Item 7.01 Regulation FD Disclosure.

Pursuant to Regulation FD, PLx Pharma Inc. (the "Company") hereby furnishes the Corporate Presentation that Natasha Giordano, the Company's President and Chief Executive Officer, and Rita O'Connor, the Company's Chief Financial Officer, will present to investors on or after March 1, 2021. The Corporate Presentation is attached hereto as Exhibit 99.1 and will be available on the Company's website under the Investor Relations tab.

The information furnished by the Company pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.




Item 8.01 Other Events.

On March 1, 2021, the Company issued a press release announcing that the U.S. Food and Drug Administration approved supplemental new drug applications for its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), the first ever novel, liquid-filled aspirin capsule. A copy of the press release is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.






Exhibit No.   Description

99.1          PLx Pharma Inc. March 2021 Corporate Presentation.
99.2          Press Release dated March 1, 2021.

© Edgar Online, source Glimpses